Disc Medicine (NASDAQ:IRON) Price Target Raised to $70.00 at Scotiabank

Disc Medicine (NASDAQ:IRONGet Free Report) had its price objective hoisted by stock analysts at Scotiabank from $62.00 to $70.00 in a note issued to investors on Tuesday, Benzinga reports. The firm presently has a “sector outperform” rating on the stock. Scotiabank’s price objective would indicate a potential upside of 8.02% from the company’s current price.

IRON has been the subject of a number of other research reports. HC Wainwright reiterated a “buy” rating and issued a $70.00 price target on shares of Disc Medicine in a report on Tuesday. Jefferies Financial Group initiated coverage on Disc Medicine in a report on Wednesday, October 23rd. They issued a “buy” rating and a $89.00 target price for the company. Morgan Stanley upgraded Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price target on the stock in a research note on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $85.00 price objective on shares of Disc Medicine in a research note on Tuesday, October 15th. Finally, Wedbush reiterated an “outperform” rating and set a $75.00 target price (up from $60.00) on shares of Disc Medicine in a report on Monday. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $80.20.

View Our Latest Stock Report on Disc Medicine

Disc Medicine Stock Performance

NASDAQ IRON opened at $64.80 on Tuesday. Disc Medicine has a 12 month low of $25.60 and a 12 month high of $77.60. The company’s 50-day moving average price is $49.06 and its 200-day moving average price is $43.19.

Disc Medicine (NASDAQ:IRONGet Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($1.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.11) by $0.08. As a group, equities research analysts expect that Disc Medicine will post -4.09 earnings per share for the current year.

Insider Buying and Selling at Disc Medicine

In other Disc Medicine news, Director William Richard White sold 7,136 shares of the stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $58.61, for a total transaction of $418,240.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 7,538 shares of company stock worth $437,875 over the last quarter. Insiders own 4.24% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Amalgamated Bank boosted its stake in Disc Medicine by 76.9% in the second quarter. Amalgamated Bank now owns 568 shares of the company’s stock valued at $26,000 after acquiring an additional 247 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Disc Medicine by 45.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock worth $54,000 after purchasing an additional 337 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Disc Medicine during the 2nd quarter valued at $129,000. SG Americas Securities LLC boosted its position in shares of Disc Medicine by 44.2% in the 2nd quarter. SG Americas Securities LLC now owns 4,071 shares of the company’s stock worth $183,000 after purchasing an additional 1,247 shares in the last quarter. Finally, ProShare Advisors LLC purchased a new position in Disc Medicine during the 1st quarter worth $211,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

About Disc Medicine

(Get Free Report)

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.

Featured Articles

Analyst Recommendations for Disc Medicine (NASDAQ:IRON)

Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter.